[go: up one dir, main page]

AR095333A1 - Composiciones nutricionales que contienen un componente peptídico y método para reducir la incidencia de enfermedad autoimune - Google Patents

Composiciones nutricionales que contienen un componente peptídico y método para reducir la incidencia de enfermedad autoimune

Info

Publication number
AR095333A1
AR095333A1 ARP140101036A ARP140101036A AR095333A1 AR 095333 A1 AR095333 A1 AR 095333A1 AR P140101036 A ARP140101036 A AR P140101036A AR P140101036 A ARP140101036 A AR P140101036A AR 095333 A1 AR095333 A1 AR 095333A1
Authority
AR
Argentina
Prior art keywords
seq
protein
source
nutritional composition
incidence
Prior art date
Application number
ARP140101036A
Other languages
English (en)
Inventor
Hondmann Dirk
A F Van Tol Eric
Gross Gabriele
H Schoemaker Marieke
Tim Lambers Teartse
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of AR095333A1 publication Critical patent/AR095333A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pediatric Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Además se refiere a los métodos para reducir la incidencia de enfermedad autoinmune y/o diabetes mellitus proveyendo dichas composiciones nutricionales a un sujeto destinatario, que incluye a un sujeto pediátrico. Reivindicación 1: Una composición nutricional caracterizada porque comprende, (i) una fuente de carbohidrato; (ii) una fuente de grasa; y (iii) una fuente equivalente de proteína, en donde a) 20% a 80% de la fuente equivalente de proteína incluye un componente peptídico que comprende SEC ID Nº 4, SEC ID Nº 13, SEC ID Nº 17, SEC ID Nº 21, SEC ID Nº 24, SEC ID Nº 30, SEC ID Nº 31, SEC ID Nº 32, SEC ID Nº 51, SEC ID Nº 57, SEC ID Nº 60, y SEC ID Nº 63; y b) 20% a 80% de la fuente equivalente de proteína comprende una proteína intacta, una proteína parcialmente hidrolizada, o combinaciones de las mismas. Reivindicación 5: La composición nutricional de la reivindicación 1, caracterizada porque comprende por lo menos un ácido graso poli-insaturado de cadena larga. Reivindicación 6: La composición nutricional de la reivindicación 5, caracterizada porque el por lo menos un ácido graso poli-insaturado de cadena larga se selecciona del grupo que consiste de ácido docosahexaenoico y ácido araquidónico. Reivindicación 7: La composición nutricional de la reivindicación 1, caracterizada porque además comprende un sobrenadante de cultivo de una fase de crecimiento exponencial tardía de un proceso de cultivo probiótico por lotes, para el uso en el tratamiento o prevención de infección por un patógeno.
ARP140101036A 2013-03-15 2014-03-14 Composiciones nutricionales que contienen un componente peptídico y método para reducir la incidencia de enfermedad autoimune AR095333A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/832,958 US9345727B2 (en) 2013-03-15 2013-03-15 Nutritional compositions containing a peptide component and uses thereof

Publications (1)

Publication Number Publication Date
AR095333A1 true AR095333A1 (es) 2015-10-07

Family

ID=50483514

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101036A AR095333A1 (es) 2013-03-15 2014-03-14 Composiciones nutricionales que contienen un componente peptídico y método para reducir la incidencia de enfermedad autoimune

Country Status (18)

Country Link
US (1) US9345727B2 (es)
EP (2) EP2986164B1 (es)
CN (2) CN105007760A (es)
AR (1) AR095333A1 (es)
AU (1) AU2014237101B2 (es)
BR (1) BR112015018264A2 (es)
CA (1) CA2905768A1 (es)
ES (1) ES2820567T3 (es)
HK (1) HK1216591A1 (es)
MX (1) MX367711B (es)
MY (1) MY169152A (es)
NZ (1) NZ709983A (es)
PE (1) PE20151999A1 (es)
PH (1) PH12015502072A1 (es)
RU (1) RU2015139971A (es)
SG (1) SG11201505533UA (es)
TW (1) TW201521602A (es)
WO (1) WO2014150556A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251928B2 (en) * 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
KR102665545B1 (ko) 2017-04-17 2024-05-13 더 유니버서티 오브 시카고 인간 건강에의 적용 및 질환의 치료를 위한 장으로의 단쇄 지방산의 전달을 위한 중합체 재료
WO2019090093A1 (en) * 2017-11-03 2019-05-09 Advanced Bionutrition Corp. Composition containing viable microorganisms and methods of making
CN109008958B (zh) * 2018-06-14 2021-10-26 中南大学湘雅医院 一种基于粪便过滤及移植的肠道菌群研究方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2064092C2 (de) 1970-12-28 1983-06-01 Bayer Ag, 5090 Leverkusen Inhibitoren für Glykosidhydrolasen aus Actinomyceten
US3937817A (en) 1973-02-28 1976-02-10 Bayer Aktiengesellschaft Pharmaceutical compositions containing a saccharase inhibitor
GB1475624A (en) 1974-07-22 1977-06-01 Toyama Chemical Co Ltd Polypeptide
FR2474829B1 (fr) 1980-02-01 1983-09-09 Agronomique Inst Nat Rech Procede de traitement d'une matiere a base de caseine contenant des phosphocaseinates de cations monovalents ou leurs derives, produits obtenus et applications
FR2474828B1 (fr) 1980-02-01 1983-09-09 Agronomique Inst Nat Rech Procede de traitement d'une matiere premiere a base de caseine, contenant des phosphocaseinates de cations bivalents, produits obtenus et application
US4491589A (en) 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
DK589785A (da) 1985-12-18 1987-06-19 Samuelsson Ernst Gunnar Peptidpraeparat, fremgangsmaade til fremstilling deraf samt anvendelse af peptidpraeparatet
IT1190349B (it) 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
FR2608050B1 (fr) 1986-12-15 1990-04-13 Bellon Labor Sa Roger Procede de preparation d'un melange peptidique riche en di- et tri-peptides, utilisable notamment en nutrition artificielle et en dietetique, melange ainsi obtenu, et utilisation de ce melange en nutrition artificielle et en dietetique
US5230902A (en) 1988-04-29 1993-07-27 Immunotec Research Corporation Undenatured whey protein concentrate to improve active systemic humoral immune response
US5102871A (en) 1989-04-24 1992-04-07 Kyowa Hakko Kogyo Co., Ltd. Nutrient composition
FI904074A7 (fi) 1989-08-28 1991-03-01 Milupa Ag Optimoidun aminohappokoostumuksen omaavat proteiini-, peptidi- ja aminohapposeokset sekä niiden käyttö keskosten ja rintalasten ravinnon sekä äidinmaidon lisäaineiden valmistamiseksi
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
PH30997A (en) 1990-03-12 1997-12-23 Ciba Geigy Antipathologenically effective compositions comprising lytic peptides and hydrolytic enzymes.
JP2731035B2 (ja) 1991-01-24 1998-03-25 マーテック・コーポレイション 微生物油混合物およびその使用
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
US5374567A (en) 1993-05-20 1994-12-20 The United States Of America As Represented By The Secretary Of The Navy Operational amplifier using bipolar junction transistors in silicon-on-sapphire
GB9312369D0 (en) 1993-06-16 1993-07-28 Sandoz Nutrition Ltd Organic compounds
US5405637A (en) 1993-06-30 1995-04-11 Bristol-Myers Squibb Company Milk protein partial hydrolysate and infant formula containing same
US5714472A (en) 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
US5723446A (en) 1993-12-23 1998-03-03 Nestec Ltd. Enteral formulation designed for optimized nutrient absorption and wound healing
US5605893A (en) 1994-03-15 1997-02-25 Children's Hospital Of Los Angeles Method of using a therapeutic food composition to diminish blood sugar fluctuations in diabetic patients
WO1996014577A1 (en) 1994-11-04 1996-05-17 The National Child Health Research Foundation Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
US5643880A (en) 1994-05-26 1997-07-01 Abbott Laboratories Product for inhibition of attachment of H. influenzae to human cells
US5821217A (en) 1995-10-27 1998-10-13 Beth Israel Deaconess Medical Center, Inc. Enteral formulation: low in fat and containing protein hydrolysates
KR100194074B1 (ko) 1996-02-21 1999-06-15 박종헌 글루텐 펩타이드를 유효성분으로 포함하는 미네랄 흡수 촉진제
CA2260892A1 (en) 1996-07-17 1998-01-22 Nicada, Inc. Appetite suppression
NL1005037C2 (nl) 1997-01-17 1998-07-20 Nl Zuivelonderzoek Inst Werkwijze voor het selectief afbreken van melkeiwit, in het bijzonder voor het selectief hydrolyseren van caseïne/caseïnaat in aanwezigheid van andere melkeiwitten, in het bijzonder wei-eiwitten.
CA2340223A1 (en) 1998-08-12 2000-02-24 Morinaga Milk Industry Co., Ltd. Nutritional compositions for preventing or treating hyperlipoproteinemia
US6077558A (en) 1998-12-23 2000-06-20 Bristol-Myers Squibb Company Elemental nutritional products
US6905702B1 (en) 1999-11-08 2005-06-14 Children's Hospital Los Angeles Methods for regulating blood glucose and appetite suppression in type 2 diabetics
GB9927603D0 (en) 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
ATE320724T1 (de) 1999-12-30 2006-04-15 Kerry Group Services Ltd Aufbaupräparat, das kohlenhydrat- und peptidmaterial enthält und sein gebrauch als energieergänzung nach oder während körperlicher übung oder als metabolischer nährstoff für die orale verabreichung
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
US6207638B1 (en) 2000-02-23 2001-03-27 Pacifichealth Laboratories, Inc. Nutritional intervention composition for enhancing and extending satiety
IL134830A0 (en) 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
US7666996B2 (en) 2000-03-01 2010-02-23 Peptera Pharmaceuticals Ltd Casein derived peptides and uses thereof
DE60127675T2 (de) 2000-06-28 2007-12-27 Fuji Nihon Seito Corp. Neuartige insulin synthase und verfahren zur herstellung von insulin durch anwendung derselben
AU1142001A (en) 2000-10-19 2002-04-29 Dsm N.V. Protein hydrolysates
WO2003005836A2 (en) 2001-07-10 2003-01-23 Trustees Of Boston University Modified-fat nutritional products useful for preventing or treating obesity
ATE372689T1 (de) 2001-07-18 2007-09-15 Dsm Ip Assets Bv Verfahren zur hydrolyse von milcheiweissen
DE10149668A1 (de) 2001-10-09 2003-04-10 Numico Res B V Insulinmimetische Aminosäuresequenzen
JP2003137804A (ja) 2001-10-31 2003-05-14 Morinaga Milk Ind Co Ltd インターロイキン−１８誘導剤
ATE353336T1 (de) 2001-11-21 2007-02-15 Morinaga Milk Industry Co Ltd Neues peptid mit angiotensinkonvertase hemmender wirkung
EP1359157A1 (en) 2002-04-29 2003-11-05 Société des Produits Nestlé S.A. Metallo-proteinase inhibitory agent
ES2540926T3 (es) 2002-06-04 2015-07-14 Dsm Ip Assets B.V. Hidrolizado de proteínas rico en tripéptidos
FR2841473B1 (fr) 2002-06-27 2004-09-17 Ingredia Utilisation d'au moins un peptide de la caseine s2 a activite inhbitrice de l'enzyme de conversion de l'engiotensine i pour la preparation de medicaments, d'aliments et de complements alimentaires
US7648957B2 (en) 2002-09-04 2010-01-19 Dsm Ip Assets B.V. Nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
TWI317636B (en) 2002-11-22 2009-12-01 Meiji Dairies Corp Nutritional compositions for liver disease patients or for patients underhigh levels of invasive stress
JPWO2004050118A1 (ja) 2002-11-29 2006-03-30 森永乳業株式会社 プロテアーゼ阻害剤
JP3955885B2 (ja) 2002-12-29 2007-08-08 日産化学工業株式会社 アディポネクチン受容体及びそれをコードする遺伝子
EP1619957A1 (en) 2003-05-05 2006-02-01 Unilever N.V. Hydrolysed casein product comprising tripeptides ipp and/ or vpp
US8524225B2 (en) 2003-09-23 2013-09-03 Dsm Ip Assets B.V. Use of proline specific endoproteases to hydrolyse peptides and proteins
EP1935425A3 (en) 2003-10-24 2008-09-03 N.V. Nutricia Immunemodulating oligosaccharides for the treatment and/or prevention of chronic obstructive pulmonary disease (COPD)
BE1015863A6 (nl) 2004-01-19 2005-10-04 Huybrechts Lucas Anticariogene proteinen & peptiden & sacchariden.
EP1718158B1 (en) 2004-01-28 2014-07-02 Andromeda Bio Tech Ltd. Hsp therapy in conjunction with a low antigenicity diet
EP1568707A1 (en) 2004-02-26 2005-08-31 Puleva Biotech, S.A. Antihypertensive peptides from casein hydrolysates
MXPA06010014A (es) * 2004-03-01 2007-03-07 Peptera Pharmaceuticals Ltd Peptidos derivados de la caseina y usos terapeuticos de los mismos.
US20080221023A1 (en) 2004-05-27 2008-09-11 Campina Nederland Holding Use of Protein Hydrolysates For the Manufacture of a Medicament For Prophylaxis and/or Treatment of a Dpp-IV Mediated Condition
DE102004040452A1 (de) 2004-08-20 2006-02-23 N.V. Nutricia Peptidgemisch
AU2005302852B2 (en) 2004-11-12 2011-06-02 N.V. Nutricia Food composition comprising a protein-and a lipid fraction for rapidly attenuating inflammatory responses
ES2381118T3 (es) 2004-12-23 2012-05-23 Campina Nederland Holding B.V. Hidrolizado de proteínas enriquecido en péptidos de inhibición de DPP-IV y su uso
JP2008527020A (ja) 2005-01-18 2008-07-24 ディーエスエム アイピー アセッツ ビー．ブイ． 新規な栄養補助組成物
PL1843778T3 (pl) 2005-02-03 2010-06-30 Dsm Ip Assets Bv Kompozycje zawierające galusan epigalokatechiny i hydrolizat białkowy
ES2321650T3 (es) 2005-02-09 2009-06-09 Unilever N.V. Productos alimenticios que comprenden solidos lacteos hidrolizados con sabor mejorado.
ATE497704T1 (de) 2005-04-28 2011-02-15 Unilever Nv Gesundheitsfördernde peptide und sie enthaltende zusammensetzungen
WO2006114439A2 (en) 2005-04-28 2006-11-02 Dsm Ip Assets B.V. Novel nutraceutical compositions
US20090074893A1 (en) 2005-04-29 2009-03-19 Campina Nederland Holding B.V. Antiviral peptides
US7618669B2 (en) * 2005-06-01 2009-11-17 Mead Johnson Nutrition Company Low-lactose partially hydrolyzed infant formula
US20060286208A1 (en) * 2005-06-01 2006-12-21 Nagendra Rangavajla Methods for producing protein partial hydrolysates and infant formulas containing the same
ES2319475B1 (es) 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion.
PT1898724E (pt) 2005-07-01 2010-11-26 Nutricia Nv Nutrição infantil com proteínas hidrolisadas
US8431531B2 (en) 2005-11-30 2013-04-30 Campina Nederland Holding B.V. Methods for stimulating glucagon-like peptide-1(GLP-1) secretion and treatments comprising same
WO2008054192A1 (en) 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
PT1800675E (pt) 2005-12-23 2011-08-30 Nutricia Nv COMPOSIÇÃO CONTENDO ÁCIDOS GORDOS POLI-INSATURADOS, PROTEÍNAS E MANGANjS E/OU MOLIBDÉNIO PARA O MELHORAMENTO DA COMPOSIÇÃO DA MEMBRANA
JP5096173B2 (ja) 2006-02-09 2012-12-12 カルピス株式会社 経口摂取用関節リウマチ抑制剤
WO2007107587A2 (en) 2006-03-22 2007-09-27 Dsm Ip Assets B.V. Cholesterol lowering protein hydrolysates
EA200802128A1 (ru) 2006-04-12 2009-04-28 ДСМ АйПи АССЕТС Б.В. Новые нутрицевтические композиции
CA2649842C (en) 2006-04-21 2015-02-17 Meiji Seika Kaisha, Ltd. Composition containing peptide as active ingredient
WO2007125946A1 (ja) 2006-04-28 2007-11-08 Snow Brand Milk Products Co., Ltd. ペプチド
KR20080003637A (ko) 2006-07-03 2008-01-08 한상기 다이어트효과가 우수한 기능성 유산균발효조성물
WO2008015374A2 (en) 2006-08-04 2008-02-07 Shs International Ltd Protein free formula
EP2049091B1 (en) 2006-08-09 2010-12-29 DSM IP Assets B.V. Casein complexes
NL1032840C2 (nl) 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
NL1033521C2 (nl) 2007-03-08 2008-09-09 Friesland Brands Bv Kindervoedingen met geoptimaliseerde aminozuursamenstelling.
WO2008127031A1 (en) 2007-04-12 2008-10-23 Industry-Academic Cooperation Foundation, Yonsei University Magnetic resonance imaging contrast agents comprising zinc-containing magnetic metal oxide nanoparticles
CA2687117A1 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
CA2688293A1 (en) 2007-05-25 2008-12-04 Childrens's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
EP2187916A2 (en) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of gluten exorphin c as a therapeutic agent
EP2230300A4 (en) 2007-10-24 2012-08-08 Otsuka Chemical Holdings Co Ltd POLYPEPTIDE WITH IMPROVED EFFECTOR FUNCTION
US8859210B2 (en) 2008-10-17 2014-10-14 Mead Johnson Nutrition Company Method for identifying allergenic proteins and peptides
JP5735734B2 (ja) 2009-04-16 2015-06-17 雪印メグミルク株式会社 脂質代謝改善剤
EP2295535A1 (en) 2009-09-11 2011-03-16 Mead Johnson Nutrition Company Probiotic material
EP2332428B1 (en) 2009-12-04 2014-08-20 MJN U.S. Holdings LLC Nutritional Formulation comprising a cow's milk peptide-containing hydrolysate and/or peptides derived thereof for tolerance induction
CA2786710C (en) * 2010-01-19 2018-10-09 Abbott Laboratories Nutritional formulas containing synbiotics
AU2011221270A1 (en) 2010-02-24 2012-09-13 Morinaga Milk Industry Co.,Ltd. Therapeutic agent for eating disorders
EP2489281A1 (en) * 2011-02-17 2012-08-22 University of Limerick A casein hydrolysate
EP2514435A1 (en) 2011-04-19 2012-10-24 Nestec S.A. Infant formula for use in the prevention of cardiovascular diseases

Also Published As

Publication number Publication date
TW201521602A (zh) 2015-06-16
NZ709983A (en) 2020-04-24
US20140271552A1 (en) 2014-09-18
PH12015502072B1 (en) 2016-01-25
MX367711B (es) 2019-09-03
AU2014237101A1 (en) 2015-08-13
ES2820567T3 (es) 2021-04-21
BR112015018264A2 (pt) 2017-08-22
AU2014237101B2 (en) 2018-04-19
US9345727B2 (en) 2016-05-24
EP2986164B1 (en) 2020-07-29
EP2986164A1 (en) 2016-02-24
CA2905768A1 (en) 2014-09-25
EP3797785A1 (en) 2021-03-31
PE20151999A1 (es) 2016-01-29
PH12015502072A1 (en) 2016-01-25
WO2014150556A1 (en) 2014-09-25
CN114041604A (zh) 2022-02-15
HK1216591A1 (zh) 2016-11-25
RU2015139971A (ru) 2017-04-24
MX2015011759A (es) 2016-01-15
CN105007760A (zh) 2015-10-28
SG11201505533UA (en) 2015-08-28
MY169152A (en) 2019-02-18

Similar Documents

Publication Publication Date Title
PE20171083A1 (es) Proceso para aumentar la estabilidad de una composicion que comprende acidos grasos omega-3 poliinsaturados
PH12013501892A1 (en) Nutritional compositions including branched chain fatty acids for wound healing
ECSP17043318A (es) Composición que contiene quitina y proteínas digeribles
PE20171082A1 (es) Proceso para aumentar la estabilidad de una composicion que comprende acidos grasos omega-6 poliinsaturados
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
NZ754232A (en) Method of processing shellfish and resulting compositions
AR095333A1 (es) Composiciones nutricionales que contienen un componente peptídico y método para reducir la incidencia de enfermedad autoimune
UY31438A1 (es) Procedimiento para reducir el contenido en acidos grasos saturados de la grasa de leche, productos obtenidos y aplicaciones del mismo.
PE20140803A1 (es) Composiciones nutricionales que tienen particulas solidas y metodos para hacer y usar las mismas
Boglino et al. Senegalese sole (Solea senegalensis) metamorphic larvae are more sensitive to pseudo-albinism induced by high dietary arachidonic acid levels than post-metamorphic larvae
MX2016014144A (es) Composiciones de proteina concentrada y metodos para su elaboracion y uso.
TR201908777A2 (tr) Suda Çözünür ve Suda Çözünür Olmayan Özellikte Yüksek Antioksidan Kapasitesine Sahip Propolis Ürünleri ve Üretim Yöntemi
MX2016009278A (es) Composicion que comprende okra para utilizarse en reducir la absorcion de grasas dieteticas.
MX2016000187A (es) Composiciones y metodos para mejorar el rendimiento del ejercicio.
BR112018011352A2 (pt) hidratação para animais
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
MX2017004662A (es) Composiciones y metodos para mejorar la movilidad o actividad o tratar la fragilidad.
WO2015123493A3 (en) Compositions and methods for modulatuion of immune response
RU2009137719A (ru) Способ производства компота вишневого с ксилитом
MX2018007529A (es) Composiciones de proteina vegetal fermentada y métodos para su producción.
BR112018004446A2 (pt) método para produzir ácido poliaspártico, composição, e, uso do ácido poliaspártico.
MX2018006026A (es) Un ligante de receptor de adenosina a3 para uso en el tratamiento de la acumulacion de grasa ectopica.
AR104721A1 (es) Fragmento fab anti-ngf humano
BR112018071142A2 (pt) métodos de fabricação de formulações nutricionais
ES2530444A1 (es) Bioencapsulación del probiótico Shewanella putrefaciens Pdp11 en alimento vivo y aplicaciones.

Legal Events

Date Code Title Description
FB Suspension of granting procedure